Today: 10 November 2025
Subscribe
Browse Category

NYSE:NVO News 9 October 2025 - 4 November 2025

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Detailed Analysis and Outlook Stock Price Trends and Technical Analysis Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week range ($20.92 – $28.00) marketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s (a ~10% jump) following its government pricing deal announcement marketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However,
4 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share reuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performance reuters.com reuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal” reuters.com. This was weeks
4 November 2025
 ·  ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Bidding War Ignites for Obesity Biotech Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bid reuters.com. This move comes just days after the foundation coup at Novo (demanding faster U.S. growth) reuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respond ts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately
31 October 2025
 ·  ·  ·  ·  ·  ·  · 
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about $4.9B) plus up to $22.50 in contingent payments sec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatment sec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wing sec.gov. On Oct. 30, Novo Nordisk dramatically entered the fray with
30 October 2025
 ·  ·  ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolio reuters.com. According to MarketScreener (Dow Jones Newswires), the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRs marketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront (about $28.50/share) plus CVRs, for up to ~$7.3B ts2.tech reuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of
30 October 2025
 ·  ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Boardroom Shake-Up Spurs Investor Nerves Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation (the company’s controlling shareholder) announced it would remove chair Helge Lund and six other independent directors. A Reuters report noted that this “boardroom coup” came amid disagreement over strategy and a push for “a sharper focus on the key U.S. market to revive sales” reuters.com reuters.com. Former CEO Lars Rebien Sørensen is set to take over as chair for 2–3 years reuters.com. Trading reacted sharply. Novo’s Copenhagen-listed shares briefly plunged 6% on Oct. 17 when President Trump
22 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levels reuters.com reuters.com and miles below the late-2024 peak (when Novo’s market cap neared $650 B) reuters.com reuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has
17 October 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Stock Performance: Recent Surge and Volatility Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 (Oct 14 close) to $10.42 by Oct 15 close investor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal (see below). Trading volume was staggering: Benzinga reports ~89.2 million shares traded (vs. a ~1.1M daily average) during the rally benzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen
16 October 2025
 ·  ·  ·  ·  ·  · 
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases investor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rights investor.omeros.com reuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the news reuters.com, and by market close had settled near $10.10 investing.com. TechStock² (ts2.tech) notes Omeros shares surged roughly 65% on the announcement ts2.tech. The deal is structured as an
15 October 2025
 ·  ·  ·  ·  ·  · 
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties novonordisk.com. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug reuters.com. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 marketscreener.com novonordisk.com. Novo’s Chief Scientific
15 October 2025
 ·  ·  ·  ·  ·  ·  · 
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech fiercebiotech.com; MarketBeat and DirectorsTalk analyst surveys marketbeat.com directorstalkinterviews.com; Economic Times deal summary economictimes.indiatimes.com economictimes.indiatimes.com; Business Wire legal alert businesswire.com businesswire.com; and TradingView market data marketbeat.com tradingview.com.
9 October 2025
 ·  ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approved reuters.com. By then, the landscape may include other new NASH therapies (possibly Lilly’s or Madrigal’s), but Novo’s combination strategy could set it apart. Wolfe Research analyst Andy Chen recently said the field has reached a “meaningful tipping point” as the first therapies emerge, predicting the leading NASH drug could see $5 billion+ in annual sales under broad use investing.com. Novo’s own management clearly shares that optimism – they
9 October 2025
 ·  ·  ·  ·  ·  · 
1 2 3 4
Go toTop